New Brunswick, NJNCT07830225Now EnrollingIRB Ready

Melanoma (Skin Cancer) Clinical Trial in New Brunswick, NJ

Access cutting-edge melanoma (skin cancer) treatment through this clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by Rutgers, The State University of New Jersey

Quick Self-Assessment

See if you qualify for this New Brunswick location

Preparing your pre-screening questions…

Expert Care in New Brunswick

Access melanoma (skin cancer) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related melanoma (skin cancer) treatment provided free

Apply for This New Brunswick Location

Check if you qualify for this melanoma (skin cancer) clinical trial in New Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Brunswick site if eligible
  4. 4Begin participation

About This Melanoma (Skin Cancer) Study in New Brunswick

This is a phase II pilot study evaluating the use of circulating tumor DNA (ctDNA) to guide the optimal duration of standard of care immune checkpoint inhibitor (ICI) therapy in patients with unresectable and/or metastatic melanoma who have radiographic evidence of disease control and/or response to treatment.

Sponsor: Rutgers, The State University of New Jersey

Who Can Participate

Inclusion Criteria

Age \> 18 with any subtype of unresectable stage III or stage IV melanoma treated with anti-PD-1-based ICI which includes both anti-PD-1 monotherapy and dual checkpoint inhibitor regimens such as ipilimumab plus nivolumab and nivolumab plus relatlimab. Disease control after at least 6-12 months of anti-PD-1-based ICI defined as a radiographic RECIST CR, PR, or SD and planned for at least 1 year of treatment OR Development of an irAE(s) on an anti-PD-1-based regimen requiring treatment interruption and immunosuppression where the investigator is considering treatment discontinuation. Patients must have a radiographic RECIST PR or CR at the treatment duration decision time point.
Any line of therapy, with the exception of adjuvant therapy.
Ability to understand and the willingness to sign a written informed consent document.
Patients with brain metastasis may be included only if there was also presence of extracranial disease.
ECOG performance status 0-2.

Exclusion Criteria

Participants who are receiving investigational therapies.
Inadequate tumor quantity or quality to conduct initial Signatera ctDNA testing.
Intracranial-only metastatic melanoma.
Patients with best response of progressive disease at time of screening.
Patients who have had their melanoma completely surgically resected such that response to immunotherapy is no longer evaluable.
Patients who are unwilling to continue or stop ICI therapy using ctDNA guidance in combination with imaging response.
History of a life-threatening or severe irAE that would make ICI rechallenge unsafe. These cases will be discussed with the Principal Investigator.
Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Brunswick?

Yes, this clinical trial (NCT07830225) has an active research site in New Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Melanoma (Skin Cancer) Treatment Options in New Brunswick, NJ

If you're searching for melanoma (skin cancer) treatment options in New Brunswick, NJ, this clinical trial (NCT07830225) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Brunswick research site is actively enrolling participants for this clinical trial. You'll receive care from experienced melanoma (skin cancer) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all melanoma (skin cancer) clinical trials near you to find additional studies recruiting in your area.

More Melanoma Trials in New Brunswick, NJ

See all melanoma clinical trials recruiting in New Brunswick — not just this study.

Browse Melanoma Trials in New Brunswick →

Browse More Trials by Condition

Melanoma TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Brunswick, NJ